Table 2.

Summary of killing activity of CTL lines directed against the PRA^100−108 peptide antigen

Normal donors	Starting responder cell population for generating CTL lines against PRA100−108	% Specific killing (30:1) (T2 + Peptide)
BC1	PBMC	5–10
BC6	CD8	15–25
BC7	PBMC	10–20
BC17	CD8	20–40
BC21	CD8+10% non-CD8 fraction	5–20
BC23	CD8	5–30
BC24	CD8 + 10% non-CD8 fraction	10–20
BC26	CD3	0–10
BC38	CD8	10–20
BC42	CD8 + 10% non-CD8 fraction	0–5
BC48	CD8 + 10% non-CD8 fraction	5–10
BC49	CD8 + 10% non-CD8 fraction	0–5
BC52	CD8 + 10% non-CD8 fraction	15–25
Melanoma patients
Patient 1	CD8	20–30
Patient 2	CD8	0–5
Patient 3	CD8	0–5
Patient 4	CD8	5–10
Patient 5	CD8	5–10
Patient 6	CD8	0–5
Patient 7	CD8	10–20
Patient 8	CD8	0–5
Patient 9	CD8	10–20
Patient 10	CD8	0–5

Several independent CTL lines were generated from each donor and the range of specific killing activities from each donor is indicated. Specific killing was defined as killing of PRA^100−108-pulsed T2 cells minus killing of unpulsed T2 cells